Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTE Outsourcing, Further Consolidation Envisioned For FDA By White House

This article was originally published in The Gray Sheet

Executive Summary

FDA's Office of the Commissioner (OC) will be consolidated further by the end of fiscal 2003 with the assistance of Booz Allen Hamilton consultants

You may also be interested in...



FDA Expects To Hire Chief Of Shared Services By July

FDA is targeting early July for selection of a candidate to oversee the agency's new Office of Shared Services, which is slated to begin operations by Oct. 1

FDA Expects To Hire Chief Of Shared Services By July

FDA is targeting early July for selection of a candidate to oversee the agency's new Office of Shared Services, which is slated to begin operations by Oct. 1

International Regulatory News In Brief

EU Presidency: Greek Health Policy Advisor Georgios Georgakoupolos receives anti-reuse partners Dec. 9 to discuss how the issue should be addressed in 2003. Stakeholders are attempting to salvage their campaign during the upcoming Greek presidency, despite being informed that EU reuse legislation is unlikely (1"The Gray Sheet" Dec. 2, 2002, p. 10). MEP Minerva Malliori offers to host a European Parliament device reuse event as early as February, agrees to forward Eucomed position on the EU drug directive review to Athens superiors, despite "strong divergences" among member states...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel